Pages that link to "Q55459523"

The following pages link to Thomas A. Lanz (Q55459523):

Displaying 31 items.

• Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease (Q27676406) (← links)
• Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities (Q27703135) (← links)
• Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. (Q33549121) (← links)
• Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of action (Q34249424) (← links)
• STEP levels are unchanged in pre-frontal cortex and associative striatum in post-mortem human brain samples from subjects with schizophrenia, bipolar disorder and major depressive disorder (Q35191367) (← links)
• MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function (Q35779169) (← links)
• Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. (Q40036225) (← links)
• Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. (Q40241539) (← links)
• Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder (Q41183343) (← links)
• Downstream effects of striatal-enriched protein tyrosine phosphatase reduction on RNA expression in vivo and in vitro. (Q42677703) (← links)
• A survey of rare coding variants in candidate genes in schizophrenia by deep sequencing. (Q42753490) (← links)
• Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014. (Q42754596) (← links)
• The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice (Q44355481) (← links)
• Robust changes in expression of brain-derived neurotrophic factor (BDNF) mRNA and protein across the brain do not translate to detectable changes in BDNF levels in CSF or plasma (Q44669549) (← links)
• Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[ (Q44725362) (← links)
• Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures (Q45038737) (← links)
• Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease (Q45299993) (← links)
• Diamide amino-imidazoles: a novel series of γ-secretase inhibitors for the treatment of Alzheimer's disease (Q46197559) (← links)
• Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies (Q46832736) (← links)
• Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype (Q47711160) (← links)
• Behavioral characterization of striatal-enriched protein tyrosine phosphatase (STEP) knockout mice. (Q47741961) (← links)
• Interactome analysis reveals ZNF804A, a schizophrenia risk gene, as a novel component of protein translational machinery critical for embryonic neurodevelopment. (Q47781553) (← links)
• Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain (Q48553009) (← links)
• Factors influencing metabolic rate in naked mole-rats (Heterocephalus glaber). (Q51456617) (← links)
• Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. (Q54212364) (← links)
• LRRK2 activation in idiopathic Parkinson's disease. (Q60143544) (← links)
• In search of the mechanisms of ketamine’s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis (Q60143545) (← links)
• H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats (Q60143548) (← links)
• Dysregulated protocadherin-pathway activity as an intrinsic defect in induced pluripotent stem cell-derived cortical interneurons from subjects with schizophrenia (Q91142967) (← links)
• GluN2D-mediated excitatory drive onto medial prefrontal cortical PV+ fast-spiking inhibitory interneurons (Q96121271) (← links)
• Schizophrenia-associated SLC39A8 polymorphism is a loss-of-function allele altering glutamate receptor and innate immune signaling (Q112726941) (← links)